Clinical Trials Browser

Recruiting × Paclitaxel × Sarcoma × Clear all

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05039801 2025-10-14

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Phase 1 Recruiting

54 enrolled

DermatologicGynecologicHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Phase 1/2 Recruiting

358 enrolled

DermatologicGastrointestinalGenitourinarySarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT05905887 2024-02-28

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Phase 2 Recruiting

48 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Clinical Trials

I-SPY

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor